Immunicom
David Lopez has over 30 years of experience in emerging growth situations, primarily in Life Sciences, serving as an attorney and transactional professional. He was a founding team member of Discovery Labs (Nasdaq: DSCO). He was highly instrumental in taking the company public and served as EVP, General Counsel, and Chief Compliance Officer overseeing legal, regulatory, and medical affairs.
He recently served as EVP, CFO, and General Counsel of PrescribeWell, a Merck portfolio company. He has provided specialized consulting services to biotech and big pharma, most recently to Insmed (Nasdaq: INSM) and as Senior Promotional Compliance/Regulatory Attorney at Otsuka.
Previously, he was a Senior Attorney at a Cravath Swain spinoff, Roberts, Sheridan & Kotel, specializing in life sciences, biotechnology, medical device, and high-technology.
Prior to that, Mr. Lopez gained investment banking experience at Drexel Burnham Lambert and served as a consultant and auditor in “Big Four” public accounting, both in NYC.
This person is not in any teams
This person is not in any offices
Immunicom
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy can allow the body’s natural immune system to directly attack cancer while enhancing the effects of other cancer treatments that may be used concurrently.